Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The diphtheria and pertussis components of diphtheria-tetanus toxoids-pertussis vaccine should be genetically inactivated mutant toxins.

The Journal of infectious diseases - 1 Jan 2005

Robbins John B, Schneerson Rachel, Trollfors Birger, Sato Hiroko, Sato Yuji, Rappuoli Rino, Keith Jerry M

Abstract excerpt

Replacement of cellular with acellular pertussis (aP) vaccines has considerably reduced the systemic reactions observed with diphtheria-tetanus toxoids-pertussis vaccine but has not eliminated the extensive swelling (sometimes involving an entire limb) observed after the fifth injection of diphtheria-tetanus toxoids-aP (DTaP) vaccine. This local reaction, which is likely an Arthus hypersensitivity reaction caused...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Child
Share to Clinical Trials as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Diphtheria Toxin

Share to Infant

Share to Mutation

Share to Pertussis Toxin

Share to Vaccination

Share to Whooping Cough

Source

Identifiers

PMID: 15593007
DOI: 10.1086/426454

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The diphtheria and pertussis components of diphtheria-tetanus toxoids-pertussis vaccine should be genetically inactivated mutant toxins.PMID 15593007Read ↗

Recombinant acellular pertussis vaccine--from the laboratory to the clinic: improving the quality of the immune response.Semantic proximity Read ↗

Acellular and "low" pertussis vaccines: adverse events and the role of mutations.Semantic proximity Read ↗

Genetically derived toxoids for use as vaccines and adjuvants.Semantic proximity Read ↗

Properties of pertussis toxin mutant PT-9K/129G after formaldehyde treatment.Semantic proximity Read ↗

Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells.Semantic proximity Read ↗

Use of pertussis toxin encoded by ptx genes from Bordetella bronchiseptica to model the effects of antigenic drift of pertussis toxin on antibody neutralization.Semantic proximity Read ↗

Mutants of cholera toxin as an effective and safe adjuvant for nasal influenza vaccine.Semantic proximity Read ↗

Characterization of mutant strains producing pertussis toxin cross reacting materials.Semantic proximity Read ↗

Immunization with a Recombinant, Pseudomonas fluorescens-Expressed, Mutant Form of Bacillus anthracis-Derived Protective Antigen Protects Rabbits from Anthrax Infection.Semantic proximity Read ↗

[Construction of the genetically attenuated bacteria Bordetella pertussis devoid of dermonecrotic toxin activity and producing modified nontoxic pertussis toxin form].Semantic proximity Read ↗

Serum antibody response to B. pertussis Tn5 mutants, purified PT and FHA in two different mouse strains and passive protection in the murine intranasal infection model.Semantic proximity Read ↗

Metabolic, humoral, and cellular responses in adult volunteers immunized with the genetically inactivated pertussis toxin mutant PT-9K/129G.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.